Crossmark

Targeting the IL-6R/STAT3/PD-L1 axis: lobaric acid and Tocilizumab as a promising combination immunotherapy in ovarian cancer

Published Online: 2025-10-09

Published Print: 2025-12

Authors

Gadashli, Ibrahim

Cansaran-Duman, Demet
Funding

Funding for this research was provided by:

Ankara Universitesi (FYL-2023-2896)

Ankara Universitesi (FYL-2023-2896)
License Information

Text and Data Mining valid from 2025-10-09

Version of Record valid from 2025-10-09
More Information

Article History

Received: 20 June 2025

Accepted: 24 September 2025

First Online: 9 October 2025

Declarations

:

: Ethical approval and permission to participate are not required for this study.

: The authors declare no competing interests.

Document is current